Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis

Supportive Care in Cancer

Volumn 14, Issue 9, 2006, Pages 917-927

  Rocchi, A ^a   Verma, S ^b  

^a Axia Research   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Anastrozole; Breast cancer; Costs; Economic evaluation; Tamoxifen

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE SYSTEM; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK REDUCTION BEHAVIOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 33747339240     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0035-8     Document Type: Article

References (51)

1. Armstrong K, Chen TM, Albert D, Randall TC, Schwartz JS (2001) Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 98:996-1003
2. ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
3. ATAC Trialists' Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98:1802-1810
4. ATAC Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139
5. Benedict A, Brown RE, Sorensen S (2004) US, UK cost-utility study of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. Medtap International (January)
6. Boccardo F, Rubagotti A, Amoroso D et al (1992) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor-positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) trial. Eur J Cancer 28:673-680
7. Bonneterre J, Buzdar A, Nabholtz JMA et al (2001) Anastrozole is superior to tamoxifen as firstline therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer 92:2247-2258
8. British Columbia Cancer Agency Cancer Management Guidelines. Endometrium. http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gynecology/ Endometrium/default.htm
9. Buzdar AU, Jonat W, Howell A et al (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83:1142-1152
10. Canadian Coordinating Office for Health Technology Assessment (1997) Guidelines for the economic evaluation of pharmaceuticals, 2nd edn. CCOHTA, Ottawa, Canada
11. Canadian Pharmaceutical Society (2004) Compendium of pharmaceuticals and specialties. Product monograph, Arimidex. Ottawa
12. Cancer Care Ontario Drug Formulary. http://www.cancercare.on.ca/ formulary/ regimensitelist1.html#adjuvant
13. Chia SKL, Speers C, Kang A et al (2003) The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer in a population based cohort. Abstract 22. American Society of Clinical Oncology annual meeting, Chicago (June)
14. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
15. Crowe JP, Gordon NH, Antunez AR et al (1991) Local-regional breast cancer recurrence following mastectomy. Arch Surg 126:429-432
16. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
17. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467
18. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339:1-15
19. Early Breast Cancer Trialists' Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28 896 women. N Engl J Med 319:1681-1692
20. Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumours. N Engl J Med 320:479-484
21. Fisher B, Dignam J, Wolmark N et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682
22. Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542
23. Fisher B, Redmond C, Legault-Poisson S et al (1990) Postoperative chemotherapy and tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018
24. Fortin A, Larochelle M, Laverdiere J et al (1999) Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and post-operative radiotherapy. J Clin Oncol 17:101-109
25. Gail MH, Costantino JP, Bryant J et al (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846
26. Gold MR, Siegel JE, Russell LB et al (1996) Cost-effectiveness in health and medicine. Oxford Univ. Press, Oxford
27. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 19:349-358
28. Hillner B (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101:1311-1322
29. Howell A et al (2003) Effect of anastrozole on bone mineral density: 2-year results of the 'arimidex' (anastrozole), tamoxifen, alone or in combination trial. San Antonio breast cancer symposium
30. Janjan NA, McNeese MD, Buzdar AV et al (1986) Management of locoregional breast cancer. Cancer 58:1552-1556
31. Lamy A, Yusuf S, Pogue J, Gafni A, HOPE Investigators (2003) Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention (Evaluation) HOPE study. Circulation 107:960-965
32. Laupacis A, Feeny D, Detsky AS et al (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146(4):473-481
33. Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ (2002) Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small cell lung cancer. J Clin Oncol 20:1344-1352
34. Locker GY (2004) Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare perspective. The ATAC Trialists' Group (abstract no. 2085). Breast Cancer Res Treat 99 (Suppl 1):105
35. Mansel RE (2005) Cost-utility analysis of anastrozole vs tamoxifen in postmenopausal women with early breast cancer from a UK national health service perspective: the 5-year completed treatment analysis of ATAC ('Arimidex', tamoxifen alone or in combination trial (abstract no. 653). J Clin Oncol 23(Suppl 16 pt. 1):41S
36. Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606
37. O'Brien BJ, Anderson DR, Goeree R (1994) Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. CMAJ 150(7):1083-1090
38. Ontario Case Costing Initiative (2005) Data analyses: average cost per CMG, 2002/2003. http://www.occp.com. Accessed March 10
39. Ontario Ministry of Health and Long-Term Care (2004) Ontario drug benefit formulary - comparative drug index, version 38. http://www.health.gov.on.ca/ english/providers/program/drugs/odbf
40. Ontario Ministry of Health and Long-Term Care (1999) Schedule of benefits for laboratory services. http://www.health.gov.on.ca/english/providers/program/ ohip/sob. April
41. Ontario Ministry of Health and Long-Term Care (2004) Schedule of benefits - physician services. http://www.health.gov.on.ca/english/providers/program/ ohip/sob. Updated November
42. Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multicentre study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391-1398
43. Pritchard KI, Paterson AHG, Fine S et al (1997) Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:2302-2311
44. Rivkin SE, Green S, Metch B et al (1994) Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen-receptor positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 12:2078-2085
45. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746
46. Statistics Canada (2002) Complete life table, Canada, 1995-1997, females. http://www.statcan.ca. Accessed October 10
47. Statistics Canada (2005) Consumer price index. http://www.statcan.ca. Accessed March 10
48. Wiktorowicz ME, Goeree R, Papaioannou A, Adachi D, Papadimitropoulos E (2001) Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 12:271-278
49. Will BP, Berthelot J, Le Petit C et al (2000) Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 36:724-735
50. Will BP, Le Petit C, Berthelot J-M et al (1999) Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. Br J Cancer 79:1428-1436
51. Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2005. J Clin Oncol 23:619-629